HK1198650A1 - (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators (4--2-) - Google Patents

(4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators (4--2-)

Info

Publication number
HK1198650A1
HK1198650A1 HK14112181.8A HK14112181A HK1198650A1 HK 1198650 A1 HK1198650 A1 HK 1198650A1 HK 14112181 A HK14112181 A HK 14112181A HK 1198650 A1 HK1198650 A1 HK 1198650A1
Authority
HK
Hong Kong
Prior art keywords
phenylimidazol
sodium channel
derivatives useful
channel modulators
ethylamine derivatives
Prior art date
Application number
HK14112181.8A
Other languages
English (en)
Chinese (zh)
Inventor
．巴加爾
．肯普
．米勒
．村田
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1198650(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of HK1198650A1 publication Critical patent/HK1198650A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK14112181.8A 2011-10-26 2014-12-03 (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators (4--2-) HK1198650A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (1)

Publication Number Publication Date
HK1198650A1 true HK1198650A1 (en) 2015-05-22

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112181.8A HK1198650A1 (en) 2011-10-26 2014-12-03 (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators (4--2-)

Country Status (28)

Country Link
US (1) US9079878B2 (ru)
EP (1) EP2771335A2 (ru)
JP (1) JP5946538B2 (ru)
KR (1) KR101586966B1 (ru)
CN (1) CN103906746B (ru)
AP (1) AP2014007579A0 (ru)
AU (1) AU2012328034B2 (ru)
BR (1) BR112014009102A2 (ru)
CA (1) CA2850925C (ru)
CL (1) CL2014000956A1 (ru)
CO (1) CO6940427A2 (ru)
CR (1) CR20140185A (ru)
CU (1) CU20140046A7 (ru)
DO (1) DOP2014000085A (ru)
EA (1) EA023375B1 (ru)
EC (1) ECSP14013324A (ru)
GT (1) GT201400079A (ru)
HK (1) HK1198650A1 (ru)
IL (1) IL232267A (ru)
MD (1) MD20140037A2 (ru)
MX (1) MX337469B (ru)
NI (1) NI201400031A (ru)
PE (1) PE20141682A1 (ru)
SG (1) SG11201401032YA (ru)
TN (1) TN2014000147A1 (ru)
UA (1) UA109220C2 (ru)
WO (1) WO2013061205A2 (ru)
ZA (1) ZA201402281B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2755980T3 (da) * 2011-09-14 2020-01-27 Dow Agrosciences Llc Fremgangsmåder og systemer til dannelse boronsyre og mellemprodukter deraf
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
EP3209303A4 (en) 2014-10-24 2017-08-30 Avectas Limited Delivery across cell plasma membranes
KR20170117170A (ko) 2015-02-19 2017-10-20 퍼듀 퍼머 엘피 위 배출을 감소시키기 위한 방법 및 조성물
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
AU2016380836A1 (en) 2015-12-30 2018-07-12 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
EP3481857A1 (en) 2016-07-06 2019-05-15 Crispr Therapeutics AG Materials and methods for treatment of pain related disorders
CA3029132A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
ES2927712T3 (es) 2017-05-16 2022-11-10 Vertex Pharma Amidas deuteradas de piridona y profármacos de las mismas como moduladores de canales de sodio
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
US20230062053A1 (en) 2019-01-10 2023-03-02 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4346818A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205778A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
NZ550769A (en) * 2004-05-07 2010-06-25 Warner Lambert Co 3- or 4-Monosubstituted phenol and thiophenol derivatives useful as H3 ligands
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
MX2007005069A (es) 2004-10-27 2007-06-25 Schering Corp Composiciones y metodos para la inhibicion del acido nucleico corto de interferencia de nav1.8.
NZ567540A (en) * 2005-12-22 2010-07-30 Newron Pharm Spa 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators
MX2009004233A (es) 2006-10-18 2009-08-12 Pfizer Prod Inc Compuestos de biaril eter urea.
DE602008000809D1 (de) 2007-03-23 2010-04-29 Icagen Inc Ionenkanal-Hemmer
CN101675040A (zh) 2007-05-03 2010-03-17 辉瑞有限公司 作为钠通道调节剂的2-吡啶甲酰胺衍生物
CA2685952C (en) 2007-05-03 2012-03-13 Pfizer Limited N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
NI201400031A (es) 2014-10-01
MX337469B (es) 2016-03-02
IL232267A (en) 2016-10-31
CA2850925A1 (en) 2013-05-02
AU2012328034A1 (en) 2014-05-15
CR20140185A (es) 2014-06-03
NZ623090A (en) 2015-10-30
CA2850925C (en) 2017-01-10
JP2014530900A (ja) 2014-11-20
CN103906746B (zh) 2015-12-09
EA023375B1 (ru) 2016-05-31
BR112014009102A2 (pt) 2017-04-18
CN103906746A (zh) 2014-07-02
AP2014007579A0 (en) 2014-04-30
WO2013061205A3 (en) 2013-06-27
CO6940427A2 (es) 2014-05-09
PE20141682A1 (es) 2014-11-14
CL2014000956A1 (es) 2014-07-18
DOP2014000085A (es) 2014-08-31
KR20140069234A (ko) 2014-06-09
AU2012328034B2 (en) 2015-04-23
SG11201401032YA (en) 2014-07-30
MX2014004738A (es) 2014-08-01
EP2771335A2 (en) 2014-09-03
UA109220C2 (ru) 2015-07-27
WO2013061205A2 (en) 2013-05-02
US9079878B2 (en) 2015-07-14
MD20140037A2 (ru) 2014-08-31
EA201490864A1 (ru) 2014-08-29
CU20140046A7 (es) 2014-10-02
KR101586966B1 (ko) 2016-01-19
WO2013061205A8 (en) 2014-03-27
GT201400079A (es) 2015-06-02
IL232267A0 (en) 2014-06-30
ZA201402281B (en) 2015-11-25
US20140296313A1 (en) 2014-10-02
JP5946538B2 (ja) 2016-07-06
TN2014000147A1 (fr) 2015-09-30
ECSP14013324A (es) 2014-05-31

Similar Documents

Publication Publication Date Title
HK1198650A1 (en) (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators (4--2-)
HK1238627A1 (zh) 作為離子通道調節劑的稠合雜環化合物
HK1200713A1 (en) Benzyl sulfonamide derivatives as rorc modulators rorc
SI2581991T1 (sl) Držalni okvir za vtični konektor
HK1201526A1 (zh) 作為 調節劑的苄基磺酰胺衍生物
PL2663550T3 (pl) Podstawione benzoazepiny jako modulatory receptora toll-podobnego
EP2663555A4 (en) SUBSTITUTED BENZOAZEPINES AS GREAT LIKE RECEPTOR MODULATORS
EP2794880A4 (en) METHODS FOR MODULATING EXPRESSION OF METASTASIS-ASSOCIATED ADENOCARCINOMA TRANSCRIPT (MALAT-1)
EP2709985A4 (en) AMINE DERIVATIVES AS BLOCKERS OF THE POTASSIUM CHANNEL
EP2568021B8 (en) Ink Composition
EP2661179A4 (en) COMPOSITION WITH REDUCED SODIUM CONTENT
EP2676553A4 (en) COMPOSITION CONTAINING CAROTENOIDS
HK1190884A1 (en) Carotenoid coloring composition
EP2659313A4 (en) Printing
HK1179956A1 (zh) 作為 調節劑的稠合雜環衍生物
IL233001A0 (en) New iso-ergoline histories
EP2688426A4 (en) SALT COMPOSITION WITH REDUCED SODIUM CONTENT
HK1196605A1 (zh) -氧代-哌啶基衍生物
AU2012902375A0 (en) Low sodium salt
AU2011903092A0 (en) Improvements Relating To Printing
GB201106990D0 (en) Connector for frames
GB201101084D0 (en) Connector for frames
GB201220680D0 (en) Antibacterials
AU2011903834A0 (en) Alignment Apparatus
AU2011903178A0 (en) 888-SuperPower (KineticEnergy2ElectricPower)

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME AND ADDRESS OF APPLICANT

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211021